Lymphoma Trial, Recruiting (NCT06131801)

Lymphoma Trial, Recruiting NCT06131801 Sponsor: Children's Hospital Medical Center, Cincinnati Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT06131801 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Patients must be under 39 years old at the time of joining the study
Patients must have been diagnosed with any type of blood cancer (such as leukaemia or lymphoma)
Patients must already have a venous or arterial line in place (a thin tube inserted into a vein or artery) that can be used for blood draws during the study
Patients must weigh at least 5.5 kilograms at the time of joining
Patients must currently be taking venetoclax in liquid form (made from crushed tablets) taken by mouth, or through a nasogastric tube (a tube through the nose to the stomach) or G-tube (a tube directly into the stomach), as prescribed by their cancer doctor
Patients may be taking venetoclax on its own or alongside other cancer treatments

Who may not be able to join:

People who are pregnant are not eligible, as venetoclax may be harmful to an unborn baby
People who are breastfeeding are not eligible, as venetoclax may pose risks to a nursing infant
People of reproductive age (male or female) who have not agreed to use an effective form of contraception throughout the study and for six months after the study treatment ends are not eligible

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 6 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lauren Pommert, MD, Children's Hospital Medical Center, Cincinnati

Phone: (513) 636-2799

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06131801

Sponsor: Children's Hospital Medical Center, Cincinnati

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: (513) 636-2799

More information: https://clinicaltrials.gov/study/NCT06131801

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Patients must be under 39 years old at the time of joining the study
Patients must have been diagnosed with any type of blood cancer (such as leukaemia or lymphoma)
Patients must already have a venous or arterial line in place (a thin tube inserted into a vein or artery) that can be used for blood draws during the study
Patients must weigh at least 5.5 kilograms at the time of joining
Patients must currently be taking venetoclax in liquid form (made from crushed tablets) taken by mouth, or through a nasogastric tube (a tube through the nose to the stomach) or G-tube (a tube directly into the stomach), as prescribed by their cancer doctor
Patients may be taking venetoclax on its own or alongside other cancer treatments

Who may not be able to join:

People who are pregnant are not eligible, as venetoclax may be harmful to an unborn baby
People who are breastfeeding are not eligible, as venetoclax may pose risks to a nursing infant
People of reproductive age (male or female) who have not agreed to use an effective form of contraception throughout the study and for six months after the study treatment ends are not eligible

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 6 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Children's Hospital Medical Center, Cincinnati

Registry

ClinicalTrials.gov

Start date

15 November 2023

Est. completion

1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Clearance (CL) as measured by PK sampling (Peripheral Blood; Required); Clearance (CL) as measured by PK sampling (Peripheral Blood; Required); Clearance (CL) as measured by PK sampling (Peripheral Blood; Required); Clearance (CL) as measured by PK sampling (Peripheral Blood; Required); Clearance (CL) as measured by PK sampling (Peripheral Blood; Required); Clearance (CL) as measured by PK sampling (Peripheral Blood; Required); Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional); Clearance (CL) as measured by PK sampling (Cerebrospinal Fluid; Optional); Clearance (CL) as...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov